<DOC>
	<DOC>NCT02821052</DOC>
	<brief_summary>This trial is conducted in Asia. The aim of this Non-interventional study is to investigate the long-term safety and effectiveness of Ryzodeg® (insulin degludec/insulin aspart) in Japanese patients with diabetes mellitus requiring insulin therapy under normal clinical practice conditions.</brief_summary>
	<brief_title>Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®</brief_title>
	<detailed_description />
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Signed consent obtained before any studyrelated activities (studyrelated activities are any procedure related to recording of data according to the protocol) The decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study Patients with diabetes mellitus requiring insulin therapy for whom the physician has decided to start treatment with Ryzodeg® Male or female, no age limitation Patients who are or have previously been treated with Ryzodeg® Previous participation in this study. Participation is defined as having given informed consent in this study Patients with a history of hypersensitivity to study product components Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>